Pan American Health Organization · 1st edition, 2020
PAHO guidance on the experimental use of convalescent plasma for COVID-19 treatment under research protocols and ethical oversight.
- Issuer
- Pan American Health Organization
- Edition
- 1st edition, 2020
- Audience
- National regulatory authorities, blood transfusion services, hospital clinicians, research ethics committees
- Evidence
- Expert consensus based on historical passive immunization experience and early COVID-19 case series
- Reviewed
- 19 Oct 2026 · GMJ
What this guideline says
GMJ summary
This PAHO document provides regulatory and operational considerations for the experimental use of convalescent plasma (CP) from recovered COVID-19 patients as a potential treatment. Written in April 2020 during the early pandemic when no proven treatments existed, it emphasizes that CP should be used only within controlled research protocols or monitored emergency use frameworks, not as routine clinical practice.
The guidance addresses the complete transfusion chain: donor eligibility and safety, blood service capacity and quality requirements, plasma collection and processing standards, pathogen testing and inactivation, patient selection criteria, and outcome monitoring. It stresses that while passive immunization has historical precedent in viral outbreaks (Argentine hemorrhagic fever, Ebola, SARS), evidence for COVID-19 efficacy remains limited and must be generated through properly designed randomized controlled trials with ethical approval.
Key recommendations include selecting donors who have been symptom-free for 14 days with two negative nasopharyngeal swabs at least 48 hours apart (or one month post-recovery), testing all plasma for transfusion-transmitted infections (HIV, HBV, HCV, syphilis), using pathogen-reduced or quarantined plasma when possible, ensuring ABO compatibility, and systematically monitoring safety outcomes including TRALI, allergic reactions, and circulatory overload alongside efficacy indicators.
Key points
For clinicians — doses and thresholds as stated in the guideline
- Donors must be confirmed COVID-19 recovered patients, symptom-free for 14 days with 2 negative nasopharyngeal swabs at least 48 hours apart, or 1 month after full recovery from confirmed infection
- All donated plasma must test negative for HIV, HBV, HCV, syphilis and other transfusion-transmitted infections per national standards
- Prefer male donors or nulliparous females, or test for anti-HLA and anti-granulocyte antibodies in parous women to minimize TRALI risk
- Use pathogen-reduced plasma (UV, detergent-solvent) or quarantined plasma when available; store at -18°C or colder for 1-year shelf life, or 2-6°C for 24 hours if thawed
- Administer only ABO-compatible convalescent plasma to recipients within approved research protocols or monitored emergency use frameworks
- Prioritize early administration (within first days of symptom onset or hospitalization) as passive immunotherapy appears more effective in early disease
- Monitor safety outcomes including TRALI, allergic reactions, circulatory overload, and efficacy indicators such as mortality, length of hospital stay, and time to negative SARS-CoV-2 molecular test
- Ensure complete traceability from donor to recipient and label plasma to indicate experimental use, pathogen reduction status if applied, and expiration date
From the guideline
Verbatim
“The safety and efficacy of convalescent plasma in the context of this epidemic are currently unproven.”
Editor’s perspective
Why this matters for Georgia and the region
Prof. Giorgi Pkhakadze, MD, MPH, PhD
Editor-in-Chief, Georgian Medical Journal · Chair, Public Health Institute of Georgia · WHO consultant, health and migration
As someone who has worked extensively with WHO on health system strengthening in the South Caucasus, I recognize this PAHO guidance as an essential template for pandemic preparedness that extends well beyond COVID-19. For Georgia, which has made significant investments in blood safety infrastructure and maintains national quality standards for transfusion services, the framework for convalescent plasma programmes can be adapted not only for future coronavirus variants but for endemic threats like Crimean-Congo haemorrhagic fever. The guidance's insistence that experimental interventions must generate systematic evidence through ethical research protocols—not merely be deployed empirically—aligns with Georgia's research ethics infrastructure and commitment to evidence-based practice. The most critical implementation challenge for our region will be ensuring that blood services have adequate apheresis capacity and pathogen reduction technologies without disrupting routine blood supplies, particularly given that many regional blood banks still operate at limited capacity and face recurring donor shortages during summer months and holiday periods.
ORCID 0000-0001-7609-4515 · Perspective written for the GMJ Guidelines Library, 19 Oct 2026
Applicability
Georgia and the South Caucasus
For Georgia and the South Caucasus, this guidance remains relevant as a framework for establishing convalescent plasma programmes for emerging infectious disease outbreaks, despite being written for COVID-19. The document’s emphasis on research protocols, ethical oversight, and integration with existing blood service infrastructure aligns with Georgia’s established national blood transfusion services and regulatory capacity. National programmes would need to assess whether existing blood banks have apheresis capacity, pathogen reduction technologies, and quality management systems meeting international standards. The guidance’s requirement for ethical committee approval and systematic outcome monitoring supports the region’s research capacity development. Given the historical use of convalescent plasma for other viral haemorrhagic fevers mentioned in the document, the framework could be adapted for outbreaks of Crimean-Congo haemorrhagic fever, which remains endemic in the region, or for future novel pathogen threats requiring rapid experimental intervention deployment.
Questions this guideline answers
Quick answers
When can a recovered COVID-19 patient donate convalescent plasma?
Donors must be symptom-free for 14 days with 2 negative nasopharyngeal swabs at least 48 hours apart using molecular testing, or alternatively 1 month after complete recovery from confirmed COVID-19 infection. They must also meet all standard blood donor eligibility criteria and test negative for all transfusion-transmitted infections.
Why is convalescent plasma considered experimental for COVID-19?
As of April 2020, evidence for convalescent plasma efficacy in COVID-19 was limited and not robust enough to establish it as effective treatment. The document emphasizes it should be used only within controlled research protocols or monitored emergency use frameworks with ethical approval, not as routine clinical practice, to generate quality scientific evidence while ensuring patient safety.
What special safety measures are needed for convalescent plasma?
Beyond standard transfusion-transmitted infection testing (HIV, HBV, HCV, syphilis), the guidance recommends using pathogen-reduced plasma when possible, preferring male or nulliparous female donors to minimize TRALI risk, ensuring complete traceability, and systematically monitoring for adverse events including TRALI, allergic reactions, circulatory overload, and possible symptom exacerbation in critically ill patients.
Which COVID-19 patients should receive convalescent plasma first?
The document recommends prioritizing recently admitted patients or those symptomatic for only a few days over those with advanced disease, as empirical studies suggest passive immunotherapy is more effective when administered early in the disease course. Patient selection should be defined within approved research protocols with clear inclusion criteria.
Related on GMJ
Interconnected resources
Dictionary of Public Health
GMJ News coverage
Quality & accreditation
- ASF Laboratory — Standard 1 — Governance & Document Control
- ASF Laboratory — Standard 6 — Pre-Examination: Specimen Pathway
- ASF Laboratory — Standard 7 — Examination: Process & Safety
- ASF Laboratory — Standard 8 — Post-Examination: Reporting & Critical Values
- ASF Hospital — Standard 5 — Safety & Emergency Preparedness
- ASF Hospital — Standard 11 — Critical Care
- ASF Medical Transport — Standard 6 — Emergency Response During Transport
Other guidelines on this topic
- Guidelines for Diagnosing and Managing Disseminated Histoplasmosis among People Living with HIV
- Interpretation of laboratory results for COVID-19 diagnosis
- Breastfeeding and COVID-19
- Dead Body Management in the Context of COVID-19
- Ethics guidance on issues raised by the novel coronavirus disease (COVID-19) pandemic
- Issuer
- Pan American Health Organization
- Type
- Procedures, manuals, guidelines
- Edition
- 1st edition, 2020
- Status
- Current
- Published
- 2020-01-01
- Languages
- English, Spanish (original)
- Scope
- Experimental use of convalescent plasma for COVID-19 treatment
- Audience
- National regulatory authorities, blood transfusion services, hospital clinicians, research ethics committees
- Licence
- CC BY-NC-SA 3.0 IGO
- Evidence
- Expert consensus based on historical passive immunization experience and early COVID-19 case series
- Record history
- Created 19 Oct 2026 · updated 19 Oct 2026 · next check Apr 2027
Pan American Health Organization. Regulatory considerations on authorization of the use of convalescent plasma (CP) to address the COVID-19 emergency, 22 April 2020. Washington, D.C.: PAHO; 2020. Available from: https://iris.paho.org/handle/10665.2/52036GMJ Guidelines Library records are original summaries written by the GMJ editorial team from the issuer’s published document and reviewed by a physician. They do not replace the full guideline. The document is the copyright of its issuer and is linked, not hosted. Spotted an error or a newer edition? Tell the Guidelines Desk.
Was this article helpful?
